1450552--12/29/2010--Dafoe_Corp.

related topics
{stock, price, share}
{product, liability, claim}
{product, candidate, development}
{stock, price, operating}
{acquisition, growth, future}
{property, intellectual, protect}
{personnel, key, retain}
{competitive, industry, competition}
Risks Related To Our Proposed Business We are an early-stage company subject to all of the risks and uncertainties of a new business. We have had no product sales to date, and we can give no assurance that there will ever be any sales in the future. There is no guarantee that our products will be accepted by consumers. We will need significant additional capital, without which we will have to curtail or cease operations. We are dependent on key personnel We will be subject to competition from numerous companies, including a number of multi-national companies, that have significantly greater financial and other resources We will have to rely on third parties to manufacture our products who may not perform to our standards or timeline. We have not yet entered into any agreements with purchasers of our products We have no patent protection and may not be able to protect our proprietary rights. We may be subject to product liability claims. Risks Related To Our Common Stock Our stock is thinly traded, so you may be unable to sell your shares at or near the quoted bid prices if you need to sell a significant number of your shares. You may have difficulty selling our shares because they are deemed penny stocks . Potential issuance of additional common stock could dilute existing stockholders. Our existing directors, officers and key employees hold a substantial amount of our common stock and may be able to prevent other stockholders from influencing significant corporate decisions. The market price of our stock may be adversely affected by market volatility.

Full 10-K form ▸

related documents
3116--3/30/2006--AKORN_INC
826253--6/15/2009--AURA_SYSTEMS_INC
3116--3/16/2007--AKORN_INC
1042610--10/13/2010--TRB_SYSTEMS_INTERNATIONAL_INC
1042610--10/13/2009--TRB_SYSTEMS_INTERNATIONAL_INC
826253--6/13/2008--AURA_SYSTEMS_INC
3116--3/16/2010--AKORN_INC
1079028--11/26/2008--VARIAN_INC
1372507--4/15/2009--RAVEN_BIOFUELS_INTERNATIONAL_CORP
826253--3/25/2008--AURA_SYSTEMS_INC
1059784--10/16/2006--GENEREX_BIOTECHNOLOGY_CORP
826253--3/25/2008--AURA_SYSTEMS_INC
1091356--3/31/2008--SEAENA_INC.
1371128--3/25/2008--BioSolar_Inc
1011733--4/15/2009--TRIMOL_GROUP_INC
1144225--4/12/2010--instaCare_Corp.
1144225--5/18/2009--instaCare_Corp.
724910--5/25/2007--NVE_CORP_/NEW/
75439--3/31/2009--CytoCore_Inc
849636--3/15/2007--CORTEX_PHARMACEUTICALS_INC/DE/
1121827--3/6/2009--BIG_SKY_INDUSTRIES_VI_INC
1121827--3/6/2009--BIG_SKY_INDUSTRIES_VI_INC
1121827--3/4/2009--BIG_SKY_INDUSTRIES_VI_INC
1121827--2/25/2009--BIG_SKY_INDUSTRIES_VI_INC
1121827--2/25/2009--BIG_SKY_INDUSTRIES_VI_INC
1121816--2/20/2009--BIG_SKY_INDUSTRIES_V_INC
1121816--2/18/2009--BIG_SKY_INDUSTRIES_V_INC
1121816--2/18/2009--BIG_SKY_INDUSTRIES_V_INC
1121816--2/13/2009--BIG_SKY_INDUSTRIES_V_INC
1121816--2/13/2009--BIG_SKY_INDUSTRIES_V_INC